Synact Pharma News Today

/PRNewswire/ -- DelveInsights Giant-Cell Arteritis Market Insights report includes a comprehensive understanding of current treatment practices, giant-cell...

New York, USA, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Musculoskeletal Pain Market Set to Observe Remunerative Growth During the Study Period (2019-2032) | DelveInsight The emergence of new products in the pipeline

/PRNewswire/ -- DelveInsights Idiopathic Membranous Nephropathy Market Insights report includes a comprehensive understanding of current treatment practices,...

SynAct Pharma AB today publishes the Annual Report for the financial year 2022. The Annual Report is attached to this press release and available on the company’s website... | April 13, 2023

Biotech company Synact Pharma visited BioStocks studio to talk about changes in the management and board. With upcoming phase II data during the autumn 2023, the company will focus more on business... | April 3, 2023

The biotech company SynAct Pharma has important clinical data coming in 2023 and recently expanded its portfolio with the acquisition of TXP Pharma. SynAct is now making a switch in management to... | April 3, 2023

The rise in the incidence of ARDS stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products to be profitable. Companies across

The rise in the incidence of ARDS stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products...

/PRNewswire/ -- Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA), a clinical-stage biotech company focused on antibody-based therapies targeting IL1RAP for...

LUND, Sweden, Feb. 1, 2023 /PRNewswire/ -- Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA), a clinical-stage biotech company focused on antibody-based therapies targeting IL1RAP for cancer